AAAAI: American Academy of Allergy, Asthma, and Immunology; ACAAI: American College of Allergy, Asthma, and Immunology; EAACI: European Academy of Allergy and Clinical Immunology; fgAH: first-generation antihistamine; LTRA: leukotriene-receptor antagonist; sgAH: second-generation antihistamine; WAO: World Allergy Organization.
* Initial omalizumab dose: 300 mg every 4 weeks.
¶ Omalizumab dose can be increased up to 600 mg every 2 weeks.
Δ Different spellings as used in the respective guidelines.
Original figure modified for this publication. From: Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. J Allergy Clin Immunol Pract 2018; 6:1144. Illustration used with the permission of Elsevier Inc. All rights reserved.